KR102706114B1 - 합성 라이신 유사체 및 모방체의 항바이러스 용도를 위한 방법 및 조성물 - Google Patents

합성 라이신 유사체 및 모방체의 항바이러스 용도를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102706114B1
KR102706114B1 KR1020207008860A KR20207008860A KR102706114B1 KR 102706114 B1 KR102706114 B1 KR 102706114B1 KR 1020207008860 A KR1020207008860 A KR 1020207008860A KR 20207008860 A KR20207008860 A KR 20207008860A KR 102706114 B1 KR102706114 B1 KR 102706114B1
Authority
KR
South Korea
Prior art keywords
arginine
tranexamic acid
virus
delete delete
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207008860A
Other languages
English (en)
Korean (ko)
Other versions
KR20200052310A (ko
Inventor
프랭크 머독
로니 머독
더블유. 폴 스테와트
Original Assignee
안티-바이럴 테크놀로지스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안티-바이럴 테크놀로지스, 엘엘씨 filed Critical 안티-바이럴 테크놀로지스, 엘엘씨
Publication of KR20200052310A publication Critical patent/KR20200052310A/ko
Application granted granted Critical
Publication of KR102706114B1 publication Critical patent/KR102706114B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207008860A 2017-08-27 2018-08-09 합성 라이신 유사체 및 모방체의 항바이러스 용도를 위한 방법 및 조성물 Active KR102706114B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762550656P 2017-08-27 2017-08-27
US62/550,656 2017-08-27
US201862664555P 2018-04-30 2018-04-30
US62/664,555 2018-04-30
PCT/US2018/046023 WO2019045989A1 (en) 2017-08-27 2018-08-09 METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF LYSINE SYNTHETIC ANALOGUES AND MIMETICS

Publications (2)

Publication Number Publication Date
KR20200052310A KR20200052310A (ko) 2020-05-14
KR102706114B1 true KR102706114B1 (ko) 2024-09-11

Family

ID=65525881

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207008860A Active KR102706114B1 (ko) 2017-08-27 2018-08-09 합성 라이신 유사체 및 모방체의 항바이러스 용도를 위한 방법 및 조성물

Country Status (11)

Country Link
US (3) US11413279B2 (https=)
EP (2) EP3672584A4 (https=)
JP (3) JP2020531586A (https=)
KR (1) KR102706114B1 (https=)
CN (1) CN111315374A (https=)
AU (2) AU2018324427B2 (https=)
BR (1) BR112020003735A2 (https=)
CA (1) CA3073685A1 (https=)
MX (2) MX2020002156A (https=)
WO (1) WO2019045989A1 (https=)
ZA (1) ZA202001472B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023505641A (ja) * 2019-10-29 2023-02-10 トラネキサミック テクノロジーズ， エルエルシー 有効性の増強のための合成リジンアナログ、誘導体、模倣物又はプロドラッグと医薬剤との相乗的組合せ
EP4103167A4 (en) * 2020-02-14 2024-03-13 Tranexamic Technologies, LLC METHODS AND COMPOSITIONS FOR THE ANTIMICROBIAL USE OF SYNTHETIC LYSINE ANALOGS, DERIVATIVES, MIMETICS AND PRODRUGS
JP7830159B2 (ja) * 2021-02-26 2026-03-16 ライオン株式会社 コロナウイルスの細胞侵入抑制剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032915A1 (ja) * 2002-10-11 2004-04-22 Daiichi Pharmaceutical Co., Ltd. 抗インフルエンザウイルス剤
US20120082677A1 (en) * 2010-10-01 2012-04-05 Sherif Salah Abdul Aziz Compositions for the treatment of hcv and hbv

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2203827A1 (en) * 1994-10-28 1996-05-09 Gerard Voerman Novel family of protease inhibitors, and other biologic active substances
WO2000037071A1 (en) * 1998-12-21 2000-06-29 Aps Kbus 8 Nr. 4788 Topical treatment of skin disease
ES2156731B1 (es) 1999-05-31 2002-02-16 Grifols Grupo Sa Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.
US7056947B2 (en) 2002-07-05 2006-06-06 Georgia Tech Research Corp. Aza-peptide epoxides
JP2008115168A (ja) * 2006-10-12 2008-05-22 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤
CA2742817A1 (en) * 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Arginine inactivation of viruses
JP2010189301A (ja) * 2009-02-17 2010-09-02 Toshihito Eto 新型インフルエンザ感染症に対する医薬組成物およびその利用
US20140271923A1 (en) * 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
CN103405384B (zh) * 2013-09-01 2015-05-13 吴静 氨甲环酸的药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032915A1 (ja) * 2002-10-11 2004-04-22 Daiichi Pharmaceutical Co., Ltd. 抗インフルエンザウイルス剤
US20120082677A1 (en) * 2010-10-01 2012-04-05 Sherif Salah Abdul Aziz Compositions for the treatment of hcv and hbv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Clinical Microbiology, 42(12), 5861-5865, 2004.

Also Published As

Publication number Publication date
US11413279B2 (en) 2022-08-16
EP3672584A1 (en) 2020-07-01
MX2020002156A (es) 2020-07-20
JP2025166032A (ja) 2025-11-05
EP4681713A2 (en) 2026-01-21
US20200323837A1 (en) 2020-10-15
JP2023123440A (ja) 2023-09-05
KR20200052310A (ko) 2020-05-14
AU2024203839A1 (en) 2024-06-27
MX2023009499A (es) 2023-08-23
AU2018324427B2 (en) 2024-03-07
ZA202001472B (en) 2022-05-25
BR112020003735A2 (pt) 2020-09-01
EP3672584A4 (en) 2021-05-05
US20260007649A1 (en) 2026-01-08
JP2020531586A (ja) 2020-11-05
CN111315374A (zh) 2020-06-19
AU2018324427A1 (en) 2020-04-09
WO2019045989A1 (en) 2019-03-07
CA3073685A1 (en) 2019-03-07
US20220288050A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
JP2023123440A (ja) 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物
Romero-Alvira et al. The keys of oxidative stress in acquired immune deficiency syndrome apoptosis
CA2533591C (en) Method for treatment of sores and lesions of the skin
JPH06507386A (ja) 治療用ペプチド
AU2003204391A1 (en) Composition and its therapeutic use
ITRM20060163A1 (it) Composizione spray ad uso topico per il tratamento e la prevenzione delle infezioni labiali da herpes simplex
RU2555765C2 (ru) Пироксикам для профилактического и терапевтического лечения герпетических инфекций
CN1213757C (zh) Dna病毒感染的协同治疗
HK40026056A (en) Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
US8092843B2 (en) Method and composition for cutaneous treatment of herpes simplex infections
CN101461817A (zh) 1,2,3,4,6-五-O-没食子酰基-b-D-葡萄糖的用途
RU2819719C2 (ru) Средство для наружного применения с противовирусным действием
US20220249416A1 (en) Synergistic combinations of synthetic lysine analogs, derivatives, mimetics, or prodrugs and pharmaceutical agents for enhanced efficacy
Bandyopadhyay et al. Systemic Review Article
Kocher A Comparative Study to Evaluate the Efficacy of Antibiotics with Placentrex® Versus Antibiotics with Dexamethasone Following Mandibular Third Molar Surgery
WO2021224790A1 (en) Vsv (vitamin c-spirulina-vitamin d) composition, kit and method
WO2009153791A1 (en) Antiviral terpenoid compounds
CZ394292A3 (cs) Preparát pro léčbu rekurentního herpesu založený na kombinaci interferonu a kofeinu

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601